WDTC1 Inhibitors
WDTC1 Inhibitors encompass a variety of chemical compounds that suppress the functional activity of WDTC1 by targeting cellular pathways and processes that necessitate the protein's involvement. Compounds such as Rapamycin, MG-132, and Bortezomib operate by inhibiting mTOR and the proteasome, respectively, thereby reducing the rate of protein synthesis and degradation, which consequently diminishes the functional demand for WDTC1. Similarly, autophagy inhibitors like Chloroquine and 3-Methyladenine (3-MA) interfere with the degradation of cellular components, further decreasing the requirement for WDTC1's role in this process. LY 294002 and Perifosine, by inhibiting PI3K and Akt signaling pathways, suppress cell growth and survival, leading to a reduced need for protein turnover and ubiquitination where WDTC1 might be implicated. WZ4003's inhibition of NUAK family kinases and C646's targeting of histone acetyltransferases modify gene expression and stress responses, in turn potentially lessening the functional activity of WDTC1.
Furthermore, Spautin-1's inhibition of Beclin1 disrupts autophagosome formation, thereby indirectly reducing the participation of WDTC1 in autophagy-related protein degradation. Axitinib's inhibition of tyrosine kinase signaling leads to decreased cellular proliferation and angiogenesis, which likely results in a lower rate of protein turnover, diminishing the need for WDTC1 function. Lastly, Oligomycin A, by impairing mitochondrial ATP synthase, cuts down the energy supply necessary for various cellular functions, including protein synthesis and degradation, thereby reducing the cellular reliance on WDTC1's role in these pathways. Collectively, these WDTC1 Inhibitors, through their targeted actions, achieve a cumulative reduction in the functional activity of WDTC1 by diminishing the cellular demand for its involvement in protein ubiquitination and degradation processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which decreases protein synthesis and cell proliferation. WDTC1, being a part of the protein degradation pathway, would have a reduced functional activity due to the lower demand for degradation processes when mTOR activity is inhibited. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that impedes the degradation of ubiquitinated proteins. Given that WDTC1 is involved in the ubiquitin-proteasome pathway, the inhibition of proteasome activity would lead to diminished functional demand on WDTC1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor which prevents the breakdown of proteins involved in cell cycle regulation. By inhibiting the proteasome, the requirement for WDTC1's role in protein ubiquitination and subsequent degradation is decreased. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
An autophagy inhibitor that prevents the maturation of autophagic vacuoles by altering the pH. This leads to reduced cellular degradation activity, indirectly decreasing the functional necessity for WDTC1. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
An inhibitor of autophagy through its action on class III PI3K. It reduces the formation of autophagosomes, and as such, can diminish the need for WDTC1's involvement in degradation pathways linked to autophagy. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor which can suppress cellular proliferation and growth signaling. Reduced PI3K activity leads to less demand for protein turnover and degradation, indirectly diminishing WDTC1's functional role. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A NUAK family kinase inhibitor which can lead to decreased cellular stress responses. Since WDTC1 can be involved in responses to stress that require protein turnover, inhibiting these kinases can reduce the need for WDTC1 activity. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
An Akt inhibitor which can lead to reduced cell survival and metabolism. By inhibiting Akt signaling, the amount of protein synthesis and subsequent requirement for degradation (and therefore WDTC1's function) is diminished. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
A selective p300/CBP histone acetyltransferase inhibitor that can lead to altered gene expression patterns. This may indirectly decrease the expression of proteins that require degradation, diminishing the role of WDTC1. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
An inhibitor of the autophagy protein Beclin1 which leads to reduced autophagosome formation. This indirectly decreases the demand for WDTC1 in the autophagic degradation pathway. | ||||||